Moderna has said it will apply for US and European emergency authorisation of its Covid-19 vaccine based on full results from a late-stage study showing its vaccine was 94.1% effective with no serious safety concerns.
It also reported a 100% success rate in preventing severe cases. The filing sets Moderna's product up to be the second vaccine likely to receive US emergency use authorisation this year. "We believe that we have a vaccine that is very highly efficacious.
We now have the data to prove it," Moderna Chief Medical Officer Dr Tal Zaks said in a telephone interview. "We expect to be playing a major part in turning around this pandemic." Dr Zaks said he was emotional after seeing the 94.1% result over the weekend: "It was the first